Drug companies see US sales plunging in Q1FY22 amidst pricing pressure, lack of new approvals

Drug companies see US sales plunging in Q1FY22 amidst pricing pressure, lack of new approvals Strides Pharma, Cipla among the companies. Strides Pharma reports net loss of Rs 21.23 crore in the first quarter of FY22. MD CEO says firm has not seen the kind of price erosion it has seen in Q1FY22.

No comments:

Post a Comment